Original-Research: Dr. Hönle AG (von NuWays AG): BUY
|
Original-Research: Dr. Hönle AG - from NuWays AG
Classification of NuWays AG to Dr. Hönle AG
Mixed Q3, FY guidance lowered but prospect remain attractive Q3 revenue fell 5.5% yoy to € 22.4m on the back of weak Adhesives business (-14.6% yoy to € 7.8m; Q1-3: -10.5% yoy to € 24.9m) as the unit struggled with persistent weakness in the automotive sector and shifting Asian electronics supply chains, which drove notable sales declines, delayed new projects, and slowed development momentum. Positively, Curing showed further stabilization with sales down only 0.6% yoy to € 8.7m (Q1-3: -1.3% yoy) while Disinfection remained on a modest growth path (Q3: +1.7% yoy to € 6.1m; Q1-3: +5.5% yoy). This reflects restructuring measures in Curing, including a focus on core competencies, discontinuation of unprofitable product lines such as solar simulation (~ € 2m sales p.a.), and cost reductions, while Disinfection benefited from higher UV lamp and component sales, especially for ballast water systems. EBITDA for the quarter came in at € 0.5m, down from € 1.4m last year (margin -3.4pp yoy to 2.3%). The decline mainly reflects soft order intake, and underutilization in parts of the business. This was particularly visible within Adhesives, which recorded a 7.9pp margin decline to 6.9%. With higher sales, the Disinfection margin climbed to 10.8% (+4.4pp yoy). Net financial debt decreased further to € 42.7m (vs. € 46m at the end of Q3 2023/24) thanks to a solid operating cash flow (Q1-3: € 3.7m) on the back of reduced working capital but also the sale of a non-core property (€ 1.3m proceeds). Worth highlighting, the majority of the financial debt (eNuW: € 30m running until mid 2038) is related to investments and loans for the group’s corporate buildings. New FY24/25 guidance. Early last week, management already cut its guidance to now € 92-94m sales (old: € 95-105m) and EBITDA of € 5-6m (old: significantly higher than the adj. EBITDA of the previous year of € 5.5m) as a result of the above described cautiousness across key end markets but also FX headwinds. Prospects remain promising. As outlined during the CMD at the beginning of the year, Hönle targets € 175m sales and a 20-25% EBITDA margin by 2030 carried by the already ongoing strategic transformation, visible in the divestment of the unprofitable sun simulation business, reduced SG&A and more importantly new solutions gaining traction (e.g. first € 250-300k sales of UV disinfection for ultra-pure water). For the time being, we remain more cautious (eNuW: € 137m sales, 6% CAGR 2024/23-2029/30e with 15% EBITDA margin) BUY with a € 16 PT based on DCF. You can download the research here: dr-honle-ag-2025-08-12-previewreview-en-33c94 For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2182502 12.08.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 107,75 | 93,88 | 115,17 | 126,50 | 106,34 | 98,72 | 93,00 | |
| EBITDA1,2 | 20,32 | 14,71 | 13,85 | 15,40 | 0,33 | 2,97 | 5,50 | |
| EBITDA-Margin3 | 18,86 | 15,67 | 12,03 | 12,17 | 0,31 | 3,01 | 5,91 | |
| EBIT1,4 | 17,00 | 8,10 | 0,35 | -10,10 | -9,42 | -10,26 | -5,00 | |
| EBIT-Margin5 | 15,78 | 8,63 | 0,30 | -7,98 | -8,86 | -10,39 | -5,38 | |
| Net Profit (Loss)1 | 12,40 | 5,61 | -4,86 | -11,90 | -10,93 | -13,00 | -6,00 | |
| Net-Margin6 | 11,51 | 5,98 | -4,22 | -9,41 | -10,28 | -13,17 | -6,45 | |
| Cashflow1,7 | 23,06 | 16,61 | 1,13 | -6,00 | 3,14 | 5,53 | 7,00 | |
| Earnings per share8 | 2,26 | 1,02 | -0,80 | -2,20 | -1,82 | -2,19 | -1,00 | |
| Dividend per share8 | 0,80 | 0,50 | 0,20 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: RSM Ebner Stolz
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Dr. Hönle | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 515710 | DE0005157101 | AG | 42,56 Mio € | 24.01.2001 | Halten | 8FWH4825+66 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 14,04 | 18,95 | 0,74 | 21,40 | 0,54 | 7,70 | 0,43 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 24.03.2026 | 24.02.2026 | 13.05.2026 | 07.08.2025 | 29.01.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -10,76% | -20,45% | -6,93% | -17,69% | -41,83% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
